Erectile dysfunction is a marker for cardiovascular disease: Results of the Minority Health Institute Expert Advisory Panel

Journal of Sexual Medicine

Volumn 2, Issue 1, 2005, Pages 40-50

  Billups, Kevin L ^a   Bank, Alan J ^a   Padma Nathan, Harin ^b   Katz, Stuart ^c   Williams, Richard ^d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular risk; Endothelial dysfunction; Erectile dysfunction; Preventive medicine

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PHOSPHODIESTERASE V INHIBITOR; VALSARTAN;

ADVISORY COMMITTEE; AGE; ALGORITHM; ARTICLE; ATHEROSCLEROSIS; CARDIOLOGY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL PRACTICE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE MARKER; DYSLIPIDEMIA; EARLY DIAGNOSIS; ENDOTHELIUM; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; EXPERT SYSTEM; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LIFESTYLE; MALE SEXUAL DYSFUNCTION; MEDICAL EXPERT; MODEL; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK MANAGEMENT; SYSTEMIC DISEASE; UROLOGY; VASCULAR DISEASE;

EID: 16344387690     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2005.20104_1.x     Document Type: Article

References (69)

1. Murray CJL, Lopez AD, editors. The Global Burden of Disease and Injury Series, volume 1: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Published by the Harvard School of Public Health on behalf of the World Health Organization and the World Bank, Harvard University Press; 1996.
2. Clark LT, Ferdinand KC, Flack JM, Gavin JR, Hall WD, Kumanyika SK, Reed JW, Saunders E, Valantine HA, Watson K, Wenger NK, Wright JT. Coronary heart disease in African Americans. Heart Dis 2001;3:97-108.
3. Gibbons GH. Physiology, genetics, and cardiovascular disease: Focus on African Americans. J Clin Hypertens 2004;6(4 suppl 1):11-18.
4. Sharma S, Malarcher AM, Giles WH, Myers G. Racial, ethnic and socioeconomic disparities in the clustering of cardiovascular disease risk factors. Ethn Dis 2004;14:43-8.
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289:2560-72.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
7. Jeremy JY, Angelini GD, Khan M, Mikhailidis DP, Morgan RJ, Thompson CS, Bruckdorfer KR, Naseem KM. Platelets, oxidant stress and erectile dysfunction: An hypothesis. Cardiovasc Res 2000; 46:50-4.
8. Jones RWA, Rees RW, Minhas S, Ralph D, Persad RA, Jeremy JY. Oxygen free radicals and the penis. Expert Opin Pharmacother 2002;3:889-97.
9. Kirby M, Jackson G, Betteridge J, Friedli K. Is erectile dysfunction a marker for cardiovascular disease? Int J Clin Pract 2001;55:614-18.
10. Maas R, Schwedhelm E, Albsmeier J, Boger RH. The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med 2002;7:213-25.
11. Feldt-Rasmussen B. Microalbuminuria, endothelial dysfunction and cardiovascular risk. Diabetes Metab 2000;26(suppl. 4):64-6.
12. Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004;43:179-84.
13. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: Endothelial dysfunction is the common denominator. Heart 2003;89:251-3.
14. NIH Consensus Development Panel on Impotence. NIH Consensus Conference: Impotence. JAMA 1993;270:83-90.
15. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342:1802-13.
16. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
17. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999;281:537-44.
18. Young JM, Bennett C, Gilhooly P, Wessells H, Ramos DE. Efficacy and safety of sildenafil citrate (Viagra®) in black and Hispanic American men. Urology 2002;60(suppl. 2B):39-48.
19. Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985;1:181-4.
20. Jackson G. Erectile dysfunction and cardiovascular disease. Int J Clin Pract 1999;53:363-8.
21. Sullivan ME, Keoghane SR, Miller MA. Vascular risk factors and erectile dysfunction. BJU Int 2001; 87:838-45.
22. Bacon CG, Hu FB, Biovannucci E, Glasser DB, Mittleman MA, Rimm EB. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 2002;25:1458-63.
23. Fedele D, Bortolotti A, Coscelli C, Santeusanio F, Chatenoud L, Colli E, Lavezzari M, Landoni M, Parazzini F, on behalf of Gruppo Italiano Studio Deficit Erettile nei Diabetici. Erectile dysfunction in type 1 and type 2 diabetics in Italy. Int J Epidemiol 2000;29:524-31.
24. Moulik PK, Hardy KJ. Hypertension, antihypertensive drug therapy and erectile dysfunction in diabetes. Diabet Med 2003;20:290-3.
25. Jensen J, Lendorf A, Stimpel H, Frost J, Ibsen H, Rosenkilde P. The prevalence and etiology of impotence in 101 male hypertensive outpatients. Am J Hypertens 1999;12:271-5.
26. Wei M, Macera CA, Davis DR, Hornung CA, Nankin HR, Blair SN. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol 1994; 140:930-7.
27. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: Results from the health professionals follow-up study. Ann Intern Med 2003;139:161-8.
28. Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKlinlay JB. Modifiable risk factors and erectile dysfunction: Can lifestyle changes modify risk? Urology 2000;56:302-6.
29. Rehman J, Melman A. Normal anatomy and physiology. In: Mulcahy JJ, editor. Male sexual function. A guide to clinical management. Totowa, NJ: Humana Press; 2001:1-46.
30. Bookstein JJ, Vandeberg J, Machado T. The cavernosal acetylcholine/papaverine response. A practical in vivo method for quantification of endothelium-dependent relaxation. Rationale and experimental validation. Invest Radiol 1990;25:1168-74.
31. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. JAMA 2002;287:719-25.
32. Manfroi WC, Caramori PR, Zago AJ, Melchior R, Zen V, Accordi M, Gutierres D, Noer C. Hemodynamic effects of sildenafil in patients with stable ischemic heart disease. Int J Cardiol 2003;90:153-7.
33. DeBusk R, Drory Y, Goldstein I, Jackson G, Kaul S, Kimmel SE, Kostis JB, Kloner RA, Lakin M, Meston CM, Mittleman M, Muller JE, Padma-Nathan H, Rosen RC, Stein RA, Zusman R. Management of sexual dysfunction in patients with cardiovascular disease: Recommendations of the Princeton Consensus Panel. Am J Cardiol 2000;86: 175-81.
34. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002;25:1336-9.
35. Jackson G, Chambers J. Sildenafil for primary pulmonary hypertension: Short and long-term symptomatic benefit. Int J Clin Pract 2002;56:397-8.
36. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000;36:845-51.
37. Wabrek AJ, Burchell RC. Male sexual dysfunction associated with coronary heart disease. Arch Sex Behav 1980;9:69-75.
38. Morley JE, Korenman SG, Kaiser FE, Mooradian AD, Viosca SP. Relationship of penile brachial pressure index to myocardial infarction and cerebrovascular accidents in older men. Am J Med 1988;84(3 Part 1):445-8.
39. O'Kane PD, Jackson G. Erectile dysfunction: Is there silent obstructive coronary artery disease? Int J Clin Pract 2001;55:219-20.
40. Basar MM, Sargon MF, Basar H, Atan A, Ak F, Celik HH, Basar R, Akalin Z. Comparative study between corpus cavernosum-electromyography findings and electron microscopy of cavernosal muscle biopsies in erectile dysfunction patients. Int J Urol 1998;5:252-5.
41. Billups KL, Kaiser DR, Kelly AS, Wetterling RA, Tsai MY, Hanson N, Bank AJ. Relation of C-reactive protein and other cardiovascular risk factors to penile vascular disease in men with erectile dysfunction. Int J Impot Res 2003;15:231-6.
42. Grover S, Kaouache M, De Carolis E, Lowensteyn I, Marchand S, Coupal L. Assessing the association between erectile dysfunction and cardiovascular disease. Preliminary results of the CANSED study (abstract #101903). Presented at the 2003 American Urological Association Annual Meeting. Chicago, IL; April 29, 2003.
43. Pritzker MR. The penile stress test: A window to the hearts of man? Circulation 1999;100(suppl 1):1-711.
44. Solomon H, Man J, Wierzbicki AS, O'Brien T, Jackson G. Erectile dysfunction: Cardiovascular risk and the role of the cardiologist. Int J Clin Pract 2003;57:96-9.
45. Jacobsen SJ, Roger VL, Jacobson DJ, Roberts RO, Girman CJ, Nehra A, Lieber MM. Erectile dysfunction and acute myocardial infarction: The Olmsted County study. Presented at the American Heart Association Scientific Sessions 2003. Orlando, FL; November 9-12, 2003.
46. Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z. Does severity of ischemic coronary disease correlate with erectile dysfunction? Int J Impot Res 1997;9:123-6.
47. Solomon H, Man JW, Wierzbicki AS, Jackson G. Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol 2003;91:230-1 .
48. Guay AT, Perez JB, Heatley GF. Cessation of smoking rapidly decreases erectile dysfunction. Endocr Pract 1998;4:23-6.
49. Guay AT, Perez JB, Jacobson J, Newton RA. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 2001;22:793-7.
50. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999;54:346-51.
51. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11:319-26.
52. Rhoden EL, Teloken C, Sogari PR, Vargas Souto CA. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res 2002;14:245-50.
53. Jorenby DE. Smoking cessation strategies for the 21st century. Circulation 2001;104:51-2.
54. Dusing R. Effect of the AT1-antagonists valsartan on sexual functioning in hypertensive men. Presented at the 18th Annual Scientific Meeting of the American Society of Hypertension. New York, NY; May 16, 2003.
55. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
56. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Östergren J, for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet 2003;361:1149-58.
57. Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: A clinical observation. J Urol 2004;172:255-8.
58. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003;26(suppl 1):S33-50.
59. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-7.
60. Scott CL. Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol 2003; 92(suppl 1A):35i-42i.
61. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
62. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003;163:427-36.
63. Okosun IS, Liao Y, Rotimi CN, Prewitt TE, Cooper RS. Abdominal adiposity and clustering of multiple metabolic syndrome in White, Black and Hispanic Americans. Ann Epidemiol 2000;10:263-70.
64. Bansal C, Guay AT, Jacobson J, Woods BO, Nesto RW. Does erectile dysfunction (ED) foreshadow cardiac disease? Incidence of metabolic syndrome and insulin resistance in an ED population. Presented at the American Association of Clinical Endocrinologists 13th annual meeting. Boston, MA; May, 2004.
65. Burns P, Gough S, Bradbury AW. Management of peripheral arterial disease in primary care. BMJ 2003;326:584-8.
66. McDermott MM. Peripheral arterial disease: Epidemiology and drug therapy. Am J Geriatr Cardiol 2002;11:258-66.
67. Jackson G, Betteridge J, Dean J, Hall R, Holdright D, Holmes S, Kirby M, Riley A, Sever P. A systematic approach to erectile dysfunction in the cardiovascular patient: A consensus statement. Int J Clin Pract 1999;53:445-51.
68. Rosen R, Goldstein I, Heiman J, Korenman S, Lakin M, Lue T, Montague DK, Padma-Nathan H, Sadovsky R, Segraves RT, Shabsigh R. The process of care model for evaluation and treatment of erectile dysfunction. The Process Care Consensus Panel. lnt J Impot Res 1999;11:59-70;discussion 70-4.
69. Harrold LR, Gurwitz JH, Field TS, Andrade SE, Fish LS, Jarry PD, Yood RA. The diffusion of a novel therapy into clinical practice: The case of sildenafil. Arch Intern Med 2000;160:3401-5.